Ivan Dannias,
Majored in Economic Sciences from Universidade Federal Fluminense and Company Management from PUC-RJ, he founded the Dannias Consultancy and Training Ltd in 2000, a company specialized in business expansion and introduction of new pharmaceutical companies into the Brazilian market.

Dannias worked as Marketing and Sales director for Abbot for 12 years where he took on several positions within Unilever Group up to commercial manager. He was responsible for market studies, availability analysis and business plan as well as the introduction of Torrent Laboratories of Brazil Ltd. into the Brazilian market.

Last month he was honored with the collar of Cândido Fontoura industrial pharmacist during the celebration of the 77º Sindusfarma anniversary.

- How do you evaluate the current global economy scenario?
Brazil has been able to pass through the global financial crisis which started in the second semester of 2008 with less difficulty than it was expected. During the second semester of last year the Brazilian economy started to recover and boosted growth in the 4º trimester.

Despite the fact that Brazil had a GDP retraction of -0,2% in 2009, the increasing result of expansion around 2% in the 4º trimester over the same period the year before, clearly showed the country had speed up its recovery and forecasted a promising 2010 economic scenario for all sectors.

Undoubtfully all the results shown in the first trimester of 2010 in all segments have made the economists feel totally optimistic once all the financial institutions have estimated positively the GDP in Brazil for this year, whose growth might be around 6 to 7%. Some institutions and businessmen claim up to 7.5%.

According to SEBRAE, even micro and small companies in the state of São Paulo had an increase in turnover by 10.2% at the end of the first trimester in 2010, when compared to the same period last year.

Therefore, we can conclude that such results are positive and motivating.

- Have the results obtained this year in the pharmaceutical industry been positive?
The pharmaceutical industry in Brazil had an amazing performance in the first trimester, over 17% until April/ 2010, and more than 20% in turnover when compared to the same period last year.

When analyzing the first four months of the year, we can notice that the three first months were excellent, with a slight retraction in April due to re-adaptation of stocks and purchases behaviors against prices in March.

The Brazilian laboratories are more professionals and have invested in research and development of products while multinationals have searched for acquisitions, mainly laboratories with good generic lines. It all heads to a great year for the pharmaceutical segment.

- Can we consider Brazil a modern window display to the world?
I wouldn't state that, though we have been growing economically since the Real Plan has been implemented, little has been done concerning infrastructure investments, law, political stability and fiscal incentives, etc. , which are essential for a safe development in order to make us consider Brazil the as a modern window display in the world.

However, I can assure that nobody doubts that Brazil might become such window.